Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Human Genome Sciences Inc | 894 |
| 2 | University of California San Diego UCSD | 498 |
| 3 | Massachusetts Institute of Technology | 464 |
| 4 | AbbVie Inc | 421 |
| 5 | Bristol Myers Squibb Co | 417 |
| 6 | Allergan Inc | 410 |
| 7 | BASF SE | 341 |
| 8 | Harvard University | 335 |
| 9 | Bayer AG | 322 |
| 10 | Novartis AG | 259 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 38,119 |
| 2 | A61P | Therapeutic activity (drug indications) | 34,206 |
| 3 | C07K | Peptides | 11,915 |
| 4 | C12N | Microorganisms, enzymes | 10,559 |
| 5 | C07D | Heterocyclic compounds | 10,213 |
| 6 | Y02A | Climate change adaptation | 8,226 |
| 7 | G01N | Investigating / analysing materials | 5,101 |
| 8 | A61L | Sterilising / disinfecting materials | 4,411 |
| 9 | C12Q | Measuring/testing involving enzymes | 3,966 |
| 10 | A01N | Preservation of bodies; biocides; pest repellents | 3,613 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Bacteriocin Bacin A4 and application thereof | 2022 | HUAIBEI NORMAL UNIVERSITY | 2 |
| SEALED BACIN. | 2000 | LOURIDO FERNANDEZ LUIS | 0 |
| A bacin flat of bed, or shit. (Machine-translation by Google Translate, not legally binding) | 1968 | Svenska Cellulosa AB | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Pneumocystis jirovecii pneumonia detection and treatment | 37 |
| 2 | Urinary Tract Infections Management | 27 |
| 3 | Antibiotic Resistance in Bacteria | 15 |
| 4 | Antibiotics Pharmacokinetics and Efficacy | 9 |
| 5 | Actinomycetales infections and treatment | 7 |
| 6 | Neutropenia and Cancer Infections | 7 |
| 7 | Pharmacological Effects and Toxicity Studies | 7 |
| 8 | Pneumonia and Respiratory Infections | 7 |
| 9 | Antibiotic Use and Resistance | 6 |
| 10 | Antimicrobial Resistance in Staphylococcus | 6 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Sherry F. Queener | Indiana University – Purdue University Indianapolis | 42 |
| 2 | Aleem Gangjee | Duquesne University | 27 |
| 3 | Allan Ronald | University of Manitoba | 13 |
| 4 | R. N. Grüneberg | University College London | 13 |
| 5 | Rudolf Then | Roche (Switzerland) | 12 |
| 6 | S. G. B. Amyes | University of London | 12 |
| 7 | J. Feeney | National Institute for Medical Research | 11 |
| 8 | W. Brumfitt | University College London | 11 |
| 9 | Anil Vasudevan | Duquesne University | 5 |
| 10 | J. M. T. Hamilton‐Miller | University College London | 10 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Projections of Global Mortality and Burden of Disease from 2002 to 2030 | 2006 | 11521 | Global Maternal and Child Health |
| A computational procedure for determining energetically favorable binding sites on biologically important macromolecules | 1985 | 2639 | Protein Structure and Dynamics |
| Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase‐trimethoprim, a drug‐receptor system | 1988 | 2057 | Protein Structure and Dynamics |
| Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis | 2002 | 960 | Liver Disease and Transplantation |
| Pneumocystis carinii Pneumonia: A Comparison Between Patients with the Acquired Immunodeficiency Syndrome and Patients with Other Immunodeficiencies | 1984 | 856 | HIV/AIDS drug development and treatment |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the chemical structure of Acuco?
What are the primary research topics associated with Acuco?
Which institutions and companies have published the most research on this compound?
What patent classifications dominate the intellectual property landscape for this compound?
How has research activity on this compound trended in recent years?